Berger Montague announces a securities class action against Tenax Therapeutics (TENX) alleging the company overstated the prospects of its lead drug TNX-103. The Phase 3 LEVEL trial failed on August 10, 2026, triggering an 89.77% stock decline. Lead plaintiff deadline is December 28, 2026.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
